Opioid formulations
AssigneeCamurus AB
InventorsFredrik Tiberg, Ian Harwigsson, Markus Johnsson
Life of this patent
Estimating the term…
Abstract
A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 1 2% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
Claims20
1-30. (canceled)
A method of treating opioid addiction in a patient, the method comprising administering to the patient a composition comprising:
- about 35% by weight of buprenorphine;
- about 14% by weight of phosphatidylcholine;
- about 21% by weight of glycerol dioleate;
- and
- about 30% by weight of N-methyl-2-pyrrolidone;
- wherein the composition is administered once monthly, and
- wherein the patient has previously received buprenorphine.
A method of treating opioid dependence in a patient, the method comprising administering to the patient a composition comprising:
- about 35% by weight of buprenorphine;
- about 14% by weight of phosphatidylcholine;
- about 21% by weight of glycerol dioleate;
- and
- about 30% by weight of N-methyl-2-pyrrolidone
- wherein the composition is administered once monthly, and
- wherein the patient has previously received buprenorphine.
Dependencies are inferred from the claim text.